Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myel...
Solid Q4e ahead, likely to end '24e with a fifth guidance upgrade Market conditions appear unchanged...
Redeye comments on announcing a new pilot involving the renowned Mayo Clinic.
Redeye adjusts its estimates after Institut Bergonié terminated the collaboration agreement to explo...
The Board of PMD Device Solutions has filed for bankruptcy following extensive reviews of the compa...
Tangiamo Touch Technology (”Tangiamo” eller ”bolaget”) meddelade den 19 december 2024 att bolaget ha...
Redeye comments on Maximum Entertainment’s divestment of certain assets within Merge Games which wil...
Redeye updates its estimates and fair value range following Ngenic’s share issue announcement and Q3...
Redeye comments on the recent funding by Smart Eye’s main competitor, Seeing Machines, which has ent...
Redeye comments briefly on Evolution’s press release regarding a review initiated by UKGC due to Evo...
On December 20, 2024, the Swedish Inspectorate of Strategic Products (ISP) concluded its review of X...
Accenture Q1'25 grew 8% (+3% vs cons), driven by a broad base Raises FY guidance from 3-6% growth to...
Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS.
Redeye is encouraged by Sivers Semiconductors’ announcement of a strengthened partnership framework ...
Enersense's wind power development portfolio has been divested, and losses from non-core operations ...
